AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01818102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Width 400 HU/Level 25 HU
Description: Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
Study NCT00096434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00096434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02485561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health communication intervention
Description: This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
Study NCT02485561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education information
Description: Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
Study NCT02485561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information
Description: Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
Study NCT04115631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04115631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT04115631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT04115631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04115631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04498143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project SAVE (Stop Adolescent Violence Everywhere) SSI
Description: Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
Study NCT04498143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supportive Therapy (Share Your Feelings) SSI
Description: Internet-based, 30-minute single session intervention to increase feelings disclosure.
Study NCT04364360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane extract
Description: 2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
Study NCT02303249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of discharges and cross-sectoral video conferencing immediately after discharge
Description: The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
Study NCT02545218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineorraphy
Description: Surgery for improperly healed perineal tear
Study NCT02545218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercise
Description: Pelvic floor exercise tutored by physio therapist.
Study NCT02915263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Study NCT02915263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Study NCT01310764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
Study NCT01310764 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trabeculectomy
Description: Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
Study NCT02916901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg
Study NCT02916901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04161937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention
Description: Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
Study NCT02728453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
Study NCT02728453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
Study NCT01567111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 11C-Metomidate Positron Emission Tomography
Description: Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
Study NCT00828230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: One application of 2mg budesonide once daily for 8 weeks
Study NCT00828230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo foam
Description: One application of placebo foam once daily for 8 weeks
Study NCT01797055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human apotransferrin
Description: intravenous infusion
Study NCT04696679 — intervention group
Intervention type: OTHER
Intervention: Patient Quality of life assessment
Description: Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
Study NCT04696679 — intervention group
Intervention type: OTHER
Intervention: Control group Quality of life assessment
Description: Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
Study NCT02489682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-form written Informed consent information
Study NCT02489682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Informed consent information
Study NCT03799237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOS trap and dengue NS1 antigen kit
Description: The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
Study NCT04136509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor elevation
Description: sinus floor elevation with the lateral technique
Study NCT04136509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone core biopsy
Description: After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
Study NCT04136509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: During reentry after bone biopsy dental implants were placed.
Study NCT04136509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography scans (CBCT)
Description: Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
Study NCT03894618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-279252
Description: The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
Study NCT02931552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nuevo Amancer-II Stress Management Program
Description: Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
Study NCT00799903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: Lp-PLA2 inhibitor administered in addition to standard therapy
Study NCT00799903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered in addition to standard therapy
Study NCT00755495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and doxepin
Description: Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
Study NCT00755495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Study NCT00755495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
Study NCT00755495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Study NCT05143034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI66207 Essence
Description: Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Study NCT05143034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Essence
Description: Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Study NCT03551626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration
Study NCT03551626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
Study NCT04438395 — intervention group
Intervention type: DEVICE
Intervention: Cardiac ablation via catheter
Description: Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
Study NCT02896283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
Study NCT02896283 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Turned-off laser
Description: Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
Study NCT02058446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan
Description: Amlodipine/Valsartan: 5 mg/80 mg
Study NCT01646086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 month behavioral weight loss intervention
Description: The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
Study NCT03597516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: powder for reconstitution for oral administration
Study NCT03461393 — intervention group
Intervention type: DEVICE
Intervention: Medical-Eye-Trainer (MET)
Description: In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
Study NCT02575261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
Study NCT01646086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 month behavioral weight loss intervention
Description: The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
Study NCT02175017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 Study in Patients With Squamous NSCLC
Study NCT03386630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine+Sufentanil
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
Study NCT03597516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: powder for reconstitution for oral administration
Study NCT01755416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Closed loop with sensor and Insulin
Description: Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
Study NCT01755416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop with sensor, Insulin and Liraglutide
Description: In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
Study NCT02696551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical education
Study NCT00445328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Description: Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
Study NCT00445328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
Study NCT03386630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine+Morphine
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
Study NCT04056650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-theanine
Description: up to 250 mg
Study NCT04056650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine supplement
Description: 50-400mg
Study NCT04056650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N1 app
Description: N1 App on mobile device
Study NCT04683185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablets.
Study NCT04683185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matched placebo tablets.
Study NCT02175017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 Study in Patients With Non-Squamous NSCLC
Study NCT01345188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranexa
Description: 1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
Study NCT01345188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
Study NCT03214354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
Study NCT03014726 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Urotronic Drug Coated Balloon (DCB)
Description: Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
Study NCT01761565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of SUF NT 15 mcg
Study NCT01761565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Study NCT00581334 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic-assisted laparoscopic sacrocolpopexy
Description: 4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
Study NCT00581334 — intervention group
Intervention type: PROCEDURE
Intervention: Open sacrocolpopexy
Description: mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
Study NCT00137306 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Facilitate evidence-based treatment for depression
Study NCT03995758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
Study NCT03214354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: TBI 300 cGy on Day -2
Study NCT03214354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is used for GVHD prophylaxis
Study NCT03532126 — intervention group
Intervention type: DEVICE
Intervention: Dermal filler for midface deficit
Description: During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
Study NCT04724915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Knee Arthroplasty
Description: People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).